Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) finished Friday with a subtraction of -$0.11 to close at $26.63, a downside of -0.41 percent. An average of 883,320 shares of common stock have been traded in the last five days. There was a gain of $2.19 in the past week, and it reached a new high 6 times over the past 12 months. The last 20 days have seen an average of 907,675 shares traded, while the 50-day average volume stands at 834,412.
RYTM stock has increased by 65.92% in the last month. The company shares reached their 1-month lowest point of $15.71 on 07/14/23. With the stock rallying to its 52-week high on 01/09/23, shares of the company touched a low of $15.50 and a high of $34.99 in 52 weeks. It has reached a new high 4 times so far this year and lost -8.55% or -$2.49 in price. In spite of this, the price is down -23.89% from the 52-week high.
Insider Transactions
RYTM stock investors should be aware that Rhythm Pharmaceuticals Inc. (RYTM) stock had its last reported insider trading activity 3 days ago on Aug 09. In this transaction, the insider spent $42,366. EVP, Head of North America, Lee Jennifer Kayden, disposed of 11,223 shares at a price of $24.18 on Aug 07. The insider now owns more than $271,347 worth of shares. Prior to that, Chief Human Resources Officer Cramer Pamela J. went on to Sale 930 shares at $17.64 each on Jul 26. An amount of $16,405 was transacted.
Valuation Metrics
Rhythm Pharmaceuticals Inc. (RYTM) stock’s beta is 1.59. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 34.23, the price-to-book (PB) ratio at 8.30.
Financial Health
The quick ratio of Rhythm Pharmaceuticals Inc. for the three months ended June 29 was 6.00, and the current ratio was 6.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.43 and a total debt to equity ratio of 0.43 for the quarter ending June 29. Rhythm Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -751.98%. Its gross profit as reported stood at $21.5 million compared to revenue of $23.64 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Rhythm Pharmaceuticals Inc.’s return on assets was -51.10%.
Earnings Surprise
For the three-month period that ended June 29, Rhythm Pharmaceuticals Inc. had $137.92 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$46.7 million in the quarter, while revenues of -$52.18 million were grew 3.64%. The analyst consensus anticipated Rhythm Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.79 per share, but it turned out to be -$0.82, a -3.80% surprise. For the quarter, EBITDA amounted to -$46.16 million. Shareholders own equity worth $56.9 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Rhythm Pharmaceuticals Inc. (RYTM) price momentum. RSI 9-day as of the close on 11 August was 90.29%, suggesting the stock is Overbought, with historical volatility in this time frame at 112.69%.
As of today, RYTM’s price is $25.63 +8.96% or $2.19 from its 5-day moving average. RYTM is currently trading +67.17% higher than its 20-day SMA and +50.45% higher than its 100-day SMA. However, the stock’s current price level is +59.84% above the SMA50 and +14.29% above the SMA200.
The stochastic %K and %D were 95.87% and 95.38%, respectively, and the average true range (ATR) was 1.28. With the 14-day stochastic at 94.03% and the average true range at 1.18, the RSI (14) stands at 85.86%. The stock has reached 1.33 on the 9-day MACD Oscillator while the 14-day reading was at 3.88.
Analyst Ratings
BofA Securities upgraded Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Rhythm Pharmaceuticals Inc. (RYTM) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RYTM, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 8 others rate it as a “buy”.
What is RYTM’s price target for the next 12 months?
Analysts predict a range of price targets between $27.00 and $52.00, with a median target of $38.00. Taking a look at these predictions, the average price target given by analysts for Rhythm Pharmaceuticals Inc. (RYTM) stock is $38.22.
